CFO tran­si­tion on the hori­zon at BioN­Tech as Sierk Po­et­ting con­cen­trates on COO du­ties; Centes­sa rides a wave of new ex­ecs af­ter An­toine Yver's ap­point­ment

Jens Hol­stein

→ As its Covid-19 vac­cine with Pfiz­er con­tin­ues to in­oc­u­late mil­lions, BioN­Tech is chang­ing CFOs be­gin­ning Ju­ly 1 with Jens Hol­stein step­ping in­to the role pre­vi­ous­ly oc­cu­pied by Sierk Po­et­ting, who will di­rect his full at­ten­tion to his work as COO mov­ing for­ward. Hol­stein was CFO at Mor­phoSys from 2011-20 and held a num­ber of lead­er­ship roles with­in the Fre­se­nius uni­verse be­fore that time.

Sierk Po­et­ting

Po­et­ting has seen BioTech turn in­to a house­hold name since his tenure be­gan in 2014, and he’s been a cru­cial voice on the vac­cine dis­tri­b­u­tion ef­forts, in­di­cat­ing some weeks ago that BioN­Tech has held dis­cus­sions on ramp­ing up ca­pac­i­ty. “There is still room for im­prove­ment. But that will ul­ti­mate­ly al­so de­pend on de­mand,” Po­et­ting told Reuters in late April.

→ The week af­ter in­tro­duc­ing An­toine Yver as CMO, Centes­sa is flesh­ing out the team with a flur­ry of new ap­point­ments, start­ing with chief tech­nol­o­gy of­fi­cer Thomas Tem­ple­man. He comes to Centes­sa af­ter near­ly two years as Nu­va­tion Bio’s SVP, phar­ma­ceu­ti­cal op­er­a­tions and qual­i­ty, and his pre­vi­ous two gigs at Ax­o­vant (SVP, phar­ma­ceu­ti­cal op­er­a­tions and qual­i­ty as­sur­ance) and Gray­bug Vi­sion (COO) were brief stays. Chief qual­i­ty of­fi­cer Tia Bush em­barks on a new chap­ter af­ter a long ca­reer at Am­gen that start­ed in 1993, clos­ing it out as chief qual­i­ty of­fi­cer and SVP, glob­al qual­i­ty/en­vi­ron­ment, health, safe­ty and sus­tain­abil­i­ty.

Two more ex­ecs are help­ing to for­mu­late Centes­sa’s C-suite with David Chao as chief ad­min­is­tra­tive of­fi­cer and Marel­la Thorell as chief ac­count­ing of­fi­cer. In Kansas City, Chao was pres­i­dent and CEO of both Bio­Med Val­ley Dis­cov­er­ies — head­quar­tered near the Coun­try Club Plaza in the Amer­i­can Cen­tu­ry build­ing — and the Stow­ers In­sti­tute for Med­ical Re­search. Thorell scores a pro­mo­tion af­ter com­ing in Jan­u­ary as head of fi­nance, and she’s been CFO at Centes­sa sub­sidiary Pal­la­dio Bio­science and Realm Ther­a­peu­tics, where she was al­so COO.

For­mer­ly of Pfiz­er and Gal­der­ma, Car­ol Stuck­ley has been named to Centes­sa’s board of di­rec­tors and chairs the au­dit com­mit­tee.

An­dre Turenne

Voy­ager is be­ing left high and dry as its CEO and pres­i­dent An­dre Turenne is jump­ing ship, re­sign­ing to “pur­sue oth­er op­por­tu­ni­ties.” Turenne’s new gig will lead him to Eu­rope, but his de­par­ture leaves the com­pa­ny at a cross­roads as it de­cides to piv­ot back to dis­cov­ery-stage ef­forts af­ter a se­ries of set­backs. In ad­di­tion to Turenne’s de­par­ture, the com­pa­ny’s CMO and R&D chief Omar Khwa­ja al­so stepped down af­ter two years at the biotech. The board is search­ing for Turenne’s re­place­ment as chair­man Michael Hig­gins will take over as in­ter­im CEO. Glenn Pierce, a board mem­ber and en­tre­pre­neur-in-res­i­dence at Third Rock, will serve as CMO.

Maria Fardis

Io­vance just got doused with more cold wa­ter from the FDA for its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) ther­a­py li­fileu­cel af­ter the agency asked for more po­ten­cy as­say da­ta. With the BLA sub­mis­sion now slat­ed for 2022, CEO Maria Fardis won’t be the one do­ing the wait­ing. Sneak­ing Fardis’ ex­it in­to an SEC fil­ing, Io­vance now turns to gen­er­al coun­sel Fred­er­ick Vogt to be pres­i­dent and CEO in the in­ter­im. Fardis had helmed the com­pa­ny since 2016.

→ Plac­ing an em­pha­sis on the North Amer­i­can mar­ket, Mer­ck KGaA is shoring up that team with Chris Round as pres­i­dent of EMD Serono in charge of the North Amer­i­ca health­care busi­ness, along with An­drew Pa­ter­son as chief mar­ket­ing of­fi­cer. Round has, with apolo­gies to Joni Mitchell, looked through life from both Mer­cks — serv­ing as the Ger­man Mer­ck’s EVP, head of in­ter­na­tion­al op­er­a­tions & glob­al core fran­chis­es just be­fore this new as­sign­ment and hold­ing lead­er­ship po­si­tions such as gen­er­al man­ag­er of the on­col­o­gy and im­munol­o­gy fran­chise at the NJ-based Mer­ck. Pa­ter­son’s been with the phar­ma as SVP, glob­al busi­ness fran­chise neu­rol­o­gy & im­munol­o­gy, fol­lowed by a brief cup of cof­fee as pres­i­dent & head of glob­al in­no­v­a­tive med­i­cine fran­chis­es.

Ox­u­ri­on has pro­mot­ed Tom Graney to steer the helm of the com­pa­ny as CEO — tak­ing over for Pa­trik De Haes, who is mov­ing in­to the role of non-ex­ec­u­tive chair­man (suc­ceed­ing Thomas Clay). Graney joined the com­pa­ny in Oc­to­ber 2020 and served as CFO. Graney pre­vi­ous­ly was CFO of Gen­er­a­tion Bio, Ver­tex, Janssen, Ethicon and Ti­botec. In ad­di­tion, he was CFO and head of cor­po­rate strat­e­gy at Iron­wood Phar­ma­ceu­ti­cals.

Tim Mayleben

→ Two of our sto­ries from this week col­lide as one with Lan­dos Bio­phar­ma — which an­nounced its part­ner­ship with Lian­Bio on Mon­day — re­serv­ing a spot for Tim Mayleben on the board of di­rec­tors. Mayleben de­cid­ed to step down as Es­pe­ri­on’s CEO on the same day the Lan­dos-Lian­Bio col­lab­o­ra­tion was re­vealed, leav­ing it to COO Shel­don Koenig to take con­trol as sales of Nexle­tol have lagged.

→ A cou­ple days ago, Per­cy Carter set­tled in­to his new role of chief sci­en­tist for Jeff Al­bers at Blue­print Med­i­cines. Carter, who had most re­cent­ly been CSO with Fi­bro­Gen, has Big Phar­ma cre­den­tials from 18 years at Bris­tol My­ers Squibb, where he was SVP and head of dis­cov­ery, among oth­er po­si­tions. He was al­so glob­al head of dis­cov­ery sci­ences for Janssen. With Ay­vak­it da­ta that “prob­a­bly ex­ceed­ed our ex­pec­ta­tions” for ad­vanced sys­temic mas­to­cy­to­sis in Sep­tem­ber, Blue­print is look­ing to out­shine No­var­tisRy­dapt in the in­di­ca­tion.

Robert Jacks

→ It’s a union of com­pa­ny name and chief ex­ec­u­tive that should be des­tined not to walk the plank: Or­biMed-backed Spar­row Phar­ma­ceu­ti­cals pre­miered this week with $54 mil­lion in Se­ries A fi­nanc­ing, and Robert Jacks has tak­en the reins as pres­i­dent and CEO. A one-time en­tre­pre­neur-in-res­i­dence at Or­biMed, Jacks cut his teeth at Pfiz­er, spend­ing the tail end of his six-year run at the phar­ma gi­ant as di­rec­tor of world­wide busi­ness de­vel­op­ment. Jacks co-found­ed Sym­bio­mix Ther­a­peu­tics and from 2018-20, he helmed In­da­lo Ther­a­peu­tics.

Tim­o­thy Noyes

→ Af­ter his elec­tion to the board of di­rec­tors in April, Boston-based car­diopul­monary dis­ease biotech Aerovate has tapped Tim­o­thy Noyes as CEO. Noyes, who put his ca­reer in gear with com­mer­cial roles at Mer­ck in the 1990s, comes off a CEO stint with Ar­cu­ate Ther­a­peu­tics and held the con­trols at Pro­teon Ther­a­peu­tics for 13 years. Found­ed by Ben Dake, Aerovate emerged from stealth last Au­gust on a $72.6 mil­lion round to de­vel­op and run tri­als for pul­monary ar­te­r­i­al hy­per­ten­sion can­di­date AV-101.

Robert Doe­bele

→ Here comes the Rain again: Robert Doe­bele made the tran­si­tion from acad­e­mia at the Uni­ver­si­ty of Col­orado to be­com­ing the CSO at Rain Ther­a­peu­tics, which he co-found­ed with Avan­ish Vel­lan­ki and oc­cu­pies a place on the list of 2021’s nine-fig­ure IPOs. This week he can add pres­i­dent to his ti­tle, and Doe­bele’s pro­mo­tion is far from the on­ly one be­ing doled out at the on­col­o­gy biotech. Ef­fec­tive last Fri­day, four staffers have been el­e­vat­ed at Rain: Vi­jaya Tiruna­garu (SVP and head of re­search); Kol­bot By (SVP, tech­ni­cal op­er­a­tions); Lu­cio Tozzi (SVP, clin­i­cal op­er­a­tions); and Nel­son Ca­bat­u­an (SVP, fi­nance & ad­min­is­tra­tion).

Deb­o­rah Kno­bel­man

→ San Fran­cis­co gene cir­cuit shop Sen­ti Bio has pro­mot­ed Curt Her­berts to COO and Philip Lee to chief tech­nol­o­gy of­fi­cer, while bring­ing in Deb­o­rah Kno­bel­man as CFO. Her­berts has been up and down the C-suite at Sen­ti Bio since his 2018 ar­rival, serv­ing as CBO and CFO af­ter he put an ex­cla­ma­tion point on his eight years at Sang­amo as CBO. He takes over for Lee, who left Mil­li­pore­Sig­ma in 2016 to help co-found Sen­ti Bio with MIT’s Tim Lu. Be­fore start­ing at Sen­ti Bio, which inked a $645 mil­lion pact with Spark a month ago, Kno­bel­man had a pre­vi­ous CFO post with Gener­i­Co Phar­ma­ceu­ti­cals and is ex-di­rec­tor, com­mer­cial strat­e­gy & an­a­lyt­ics for Pfiz­er’s pri­ma­ry care busi­ness.

Jessie Han­ra­han

Aa­van­tiBio is liv­ing rent-free in Peer Re­view as the staff grows, with chief reg­u­la­to­ry of­fi­cer Jessie Han­ra­han be­com­ing the fifth se­nior ex­ec in two months to make her home at the Cam­bridge, MA gene ther­a­py play­er. Like David David­son and Joanne Smith-Far­rell be­fore her, Han­ra­han is in the club of folks who have left blue­bird bio — as se­nior di­rec­tor and then VP of reg­u­la­to­ry sci­ence, she worked on sub­mit­ting the mar­ket­ing au­tho­riza­tion ap­pli­ca­tion for, and the ap­proval of, Zyn­te­glo. Since March, Aa­van­tiBio CEO Bo Cum­bo has hired CFO Dou­glas Swirsky, COO Ty How­ton, CMO Christo­pher Wright, and CTO Paul Herzich.

→ This be­ing PGA Cham­pi­onship week, Fore Bio­ther­a­peu­tics is aim­ing straight down the mid­dle of the fair­way with the ad­di­tions of Sta­cie Pea­cock Shep­herd as CMO and No­ra Bren­nan as CFO. Shep­herd, an Ab­bott and Ab­b­Vie vet, comes to the Philadel­phia on­col­o­gy play­er from QED Ther­a­peu­tics, spend­ing a year there as SVP of clin­i­cal de­vel­op­ment. Bren­nan has CFO cred­its from TELA Bio and Xeris Phar­ma­ceu­ti­cals. Last­ly at Fore, ex-Pro­teosta­sis Ther­a­peu­tics pres­i­dent and CEO Meenu Chhabra has jumped on to the board of di­rec­tors.

Dale Sander

Dale Sander is suc­ceed­ing Doug Blanken­ship as CFO of Lau­ra Nikla­son-led Hu­ma­cyte, which vault­ed on­to Nas­daq in Feb­ru­ary in a $255 mil­lion SPAC deal with Ra­jiv Shuk­la. Sander, a board mem­ber at Hu­ma­cyte since 2015, has al­so re­moved the “act­ing” la­bel from his role of chief cor­po­rate de­vel­op­ment of­fi­cer and will be Hu­ma­cyte’s trea­sur­er as well. Sander was most re­cent­ly CFO of an­oth­er North Car­oli­na com­pa­ny, Bryn Phar­ma.

→ With its sec­ond Peer Re­view ap­pear­ance in as many weeks, Log­icBio has pro­mot­ed Daniel Gruskin to CMO while nam­ing Stephen Boy­er VP of reg­u­la­to­ry and qual­i­ty af­fairs and Pe­ter Pechan VP of gene ther­a­py. Gruskin be­came Log­icBio’s SVP and head of clin­i­cal de­vel­op­ment nine months ago af­ter a run at Sanofi Gen­zyme that in­clud­ed get­ting bumped up to VP, head of glob­al med­ical af­fairs, rare dis­ease. Boy­er had worked for a strong line­up of big names — Bio­gen, Bris­tol My­ers, Boehringer In­gel­heim and Bay­er — be­fore his most re­cent gig as head of reg­u­la­to­ry at Boston Phar­ma­ceu­ti­cals. And Pechan, who brings gene ther­a­py ex­pe­ri­ence from Bio­gen and Sanofi Gen­zyme, had been se­nior di­rec­tor of R&D and head of vec­tor bi­ol­o­gy for Sol­id Bio­sciences.

De­bra Hus­sain

Eli Lil­ly alum De­bra Hus­sain has signed on as chief com­mer­cial of­fi­cer for Aca­cia Phar­ma, which won two FDA ap­provals in 2020 — one for its in­tra­venous for­mu­la­tion of amisul­pride, and the oth­er for remi­ma­zo­lam. With Aca­cia’s US head­quar­ters in In­di­anapo­lis, Hus­sain stays in the Cross­roads of Amer­i­ca af­ter more than 20 years at Lil­ly that saw her rise to se­nior di­rec­tor of mar­ket­ing for the phar­ma gi­ant.

Gain­ing break­through ther­a­py des­ig­na­tion by the FDA in De­cem­ber for its ty­ro­sine ki­nase in­hibitor re­potrec­tinib to treat non-small cell lung can­cer, San Diego’s Turn­ing Point Ther­a­peu­tics has se­lect­ed Ku­mar Srini­vasan as CBO. Srini­vasan hails from As­traZeneca, where he con­clud­ed his nine years at the phar­ma gi­ant as VP and glob­al head of busi­ness de­vel­op­ment for the bio­phar­ma­ceu­ti­cal busi­ness unit.

Bradley Glover

→ Pla­cen­ta-based CAR-T biotech Celu­lar­i­ty (not to be con­fused with Flag­ship’s Cel­lar­i­ty) has en­list­ed Roche and Genen­tech vet Bradley Glover as chief tech­nol­o­gy of­fi­cer. Glover makes the switch to the NK de­vel­op­er af­ter four and a half years at Kite, serv­ing as VP, cor­po­rate de­vel­op­ment, head of cor­po­rate strat­e­gy and op­er­a­tions be­fore join­ing Robert Hariri’s squad.

Ire­na Mel­niko­va

→ Fol­low­ing the ad­di­tion of CMO Nush­mia Khokhar last month, Seat­tle-based Umo­ja Bio­phar­ma has wel­comed Ire­na Mel­niko­va as CFO. Mel­niko­va, the ex-di­rec­tor of strat­e­gy and ex­ter­nal in­no­va­tion at Sanofi, was a man­ag­ing di­rec­tor in in­vest­ment bank­ing at SVB Leerink and just spent sev­en years there over­all be­fore mov­ing on to Umo­ja, a gene ther­a­py biotech us­ing its $53 mil­lion Se­ries A to de­vel­op its pipeline of in vi­vo CAR-T ther­a­pies.

→ Ger­man rare dis­ease biotech Cen­to­gene has pegged Michael Motz as chief com­mer­cial of­fi­cer, phar­ma­ceu­ti­cals af­ter re­plac­ing CEO Arndt Rolfs with An­drin Os­wald in Oc­to­ber. With ar­ti­fi­cial in­tel­li­gence a fo­cal point in Cen­to­gene’s drug dis­cov­ery ef­forts, Motz — a for­mer di­rec­tor of busi­ness de­vel­op­ment at Roche — has been head of busi­ness de­vel­op­ment AI at MAB Dis­cov­ery and Zealand Phar­ma.

San­dra Ro­jas-Caro

San­dra Ro­jas-Caro will be CMO of Pitts­burgh’s NeuBase Ther­a­peu­tics start­ing Mon­day, the lat­est C-suite hire at the gene si­lenc­ing biotech af­ter COO William Mann and CSO Curt Brad­shaw jumped aboard in the last nine months. Ro­jas-Caro has for­mer­ly been CMO at Gem­i­ni Ther­a­peu­tics and Ae­glea Bio­Ther­a­peu­tics, both of which came af­ter her time in R&D at Synage­va and Alex­ion.

Tariq Ar­shad is tak­ing on the role of CMO at Carls­bad, CA-based can­cer and in­fec­tious dis­ease biotech Quali­gen Ther­a­peu­tics. Ar­shad has spent the last two years as glob­al head of med­ical af­fairs and clin­i­cal re­search at Bec­ton Dick­in­son, and pri­or to that he was Sanofi Gen­zyme’s head of med­ical af­fairs for the im­munol­o­gy fran­chise (Dupix­ent and Kevzara). Fur­ther­more, he has held lead­er­ship po­si­tions at Pfiz­er, Mer­ck and Genen­tech.

Cather­ine Ball

→ Just be­cause the FTC put the ki­bosh on Il­lu­mi­na’s $1.2 buy­out of Pa­cif­ic Bio­sciences doesn’t mean PacBio can’t dip in­to Il­lu­mi­na’s tal­ent pool. Kathy Lynch, PacBio’s new head of glob­al gov­ern­ment af­fairs and cor­po­rate com­mu­ni­ca­tions, was Il­lu­mi­na’s VP of glob­al gov­ern­ment Af­fairs and pub­lic pol­i­cy; new chief ac­count­ing of­fi­cer Michele Farmer start­ed at Il­lu­mi­na in 2009 and was the se­quenc­ing com­pa­ny’s se­nior di­rec­tor of ac­count­ing. Else­where, Cather­ine Ball has joined PacBio as SVP of re­search af­ter nine years at An­ces­tryD­NA, five of them as CSO.

→ Alzheimer’s-fo­cused Cog­ni­to Ther­a­peu­tics has called up­on Ever­est Crosland to be chief com­mer­cial of­fi­cer af­ter hold­ing the same po­si­tion at Ap­plied­VR. Fur­ther back, Crosland was VP of mar­ket ac­cess & re­im­burse­ment for Pear Ther­a­peu­tics and se­nior di­rec­tor, pric­ing and re­im­burse­ment strat­e­gy. Crosland’s ap­point­ment comes two weeks af­ter Cog­ni­to brought on Jonathan Lieber as CFO.

Vi­jay Kar­w­al

Vi­jay Kar­w­al has got­ten the nod to be CFO of Shang­hai-based Af­faMed Ther­a­peu­tics, zoom­ing in on oph­thalmic, neu­ro­log­i­cal and psy­cho­log­i­cal dis­or­ders and com­pil­ing $170 mil­lion in a Se­ries B round. Kar­w­al was pre­vi­ous­ly No­mu­ra In­ter­na­tion­al’s man­ag­ing di­rec­tor and head of health­care in­vest­ment bank­ing for the Asia (ex-Japan) re­gion, and he’s al­so been a man­ag­ing di­rec­tor for CIMB and Roy­al Bank of Scot­land.

→ Can­cer-fo­cused Onc­ter­nal Ther­a­peu­tics out of San Diego has made No­var­tis and J&J vet Sal­im Yazji CMO. Yazji, who was VP & glob­al head of on­col­o­gy at Bax­ter for two years, co-found­ed and helmed im­muno-on­col­o­gy out­fit Aju­ta Ther­a­peu­tics be­fore mak­ing the jump to Onc­ter­nal. He’s al­so the ex-CMO of PMV Phar­ma.

Gopi Shanker

Tevard Bio­sciences is adding a new face to its lead­er­ship team with the ap­point­ment of Gopi Shanker as CSO. Shanker hops aboard from the NI­BR, where he most re­cent­ly served as head of neu­ro­science. Pri­or to that, worked on ad­vanc­ing drugs like Aimovig to ap­proval at No­var­tis and had stints at Am­gen and Re­gen­eron.

Au­los Bio­science has brought on Leo Red­mond as CFO. Red­mond re­cent­ly served as CFO of Al­lakos and pre­vi­ous­ly served at Pre­sidio Phar­ma­ceu­ti­cals and Genen­tech.

Qi Wei

→ Los An­ge­les-based Ap­pia Bio — fo­cused on de­vel­op­ing en­gi­neered al­lo­gene­ic cell ther­a­pies from hematopoi­et­ic stem cells for can­cer pa­tients — has reeled in Qi Wei as SVP and head of tech­ni­cal op­er­a­tions. Wei makes the leap from Gene­cep­tion Ther­a­peu­tics, which he co-found­ed as an ex­ec­u­tive-in-res­i­dence at F-Prime Cap­i­tal. In ad­di­tion to that, Wei brings in a wealth of ex­pe­ri­ence from his times at No­var­tis, Kite, Eli Lil­ly and TCR2 Ther­a­peu­tics.

→ Life sci­ences VC For­bion has named Jasper Bos as gen­er­al part­ner. Bos was for­mer­ly SVP and man­ag­ing di­rec­tor at M Ven­tures, the ven­ture arm of Mer­ck.

→ Prince­ton, NJ-based biosim­u­la­tion soft­ware com­pa­ny Cer­tara, a late en­try in the Great IPO Gold Rush of 2020, has put to­geth­er a quar­tet of moves and wel­comed the fol­low­ing: Matt Zier­hut (VP, mod­el-based meta-analy­sis); James Dun­yak (se­nior di­rec­tor, bio­sta­tis­tics and da­ta pro­gram­ming); Su­san Potts (se­nior di­rec­tor, bio­sta­tis­tics and da­ta pro­gram­ming); and Josh Xie (di­rec­tor, clin­i­cal phar­ma­col­o­gy and trans­la­tion­al med­i­cine).

Zier­hut spent his last five years with Janssen as di­rec­tor of quan­ti­ta­tive sci­ences, while Dun­yak is a No­var­tis vet who was pre­vi­ous­ly As­traZeneca’s se­nior di­rec­tor of clin­i­cal phar­ma­co­met­rics. Potts has worked in bio­sta­tis­tics at Rea­ta, En­do Phar­ma­ceu­ti­cals and most re­cent­ly, Ae­glea Bio­Ther­a­peu­tics. Fi­nal­ly, Xie — whose work will be cen­tered around part­ner­ships with com­pa­nies in Chi­na and oth­er multi­na­tion­als — has held posts at Pfiz­er and the FDA.

On­coSec has re­cruit­ed Robert Schi­nagl as VP of pro­gram and al­liance man­age­ment. Schi­nagl joins the com­pa­ny from Prothex Phar­ma, where he was COO. Pri­or to Prothex, Schi­nagl served at Drais Phar­ma­ceu­ti­cals, Eli Lil­ly, Im­Clone Sys­tems and Osiris Ther­a­peu­tics, among oth­ers.

Manuel Hi­dal­go Med­i­na

→ Bris­tol My­ers has made room for Manuel Hi­dal­go Med­i­na on its board of di­rec­tors, ef­fec­tive June 1. Med­i­na, chief of hema­tol­ogy and med­ical on­col­o­gy at Weill Cor­nell Med­i­cine and New York-Pres­by­ter­ian/Weill Cor­nell Med­ical Cen­ter, will be the 11th mem­ber of a board chaired by CEO Gio­van­ni Caforio.

Notch­ing an up­sized IPO in March, IBD-fo­cused Prometheus Bio­sciences has made Fred Has­san a part of its board of di­rec­tors. Has­san, the ex-chair­man and CEO of Scher­ing-Plough and a board mem­ber at Am­gen since 2015, is di­rec­tor at War­burg Pin­cus.

Re­lay Ther­a­peu­tics pres­i­dent and CEO San­jiv Pa­tel is mak­ing the leap on­to the board of di­rec­tors of Prothena. Pri­or to his gig at Re­lay, Pa­tel served in a va­ri­ety of roles at Al­ler­gan such as EVP, chief strat­e­gy of­fi­cer and cor­po­rate vice pres­i­dent, glob­al strate­gic mar­ket­ing and glob­al health out­comes.

Roger Dansey

Seagen CMO Roger Dansey has been elect­ed to In­ovio’s board of di­rec­tors a month af­ter the De­part­ment of De­fense put a lid on fund­ing the Phase III tri­al of the biotech’s Covid-19 vac­cine. Dansey has been an on­col­o­gy ex­ec at Mer­ck, Gilead and Am­gen.

Jean-Pierre Som­ma­dos­si has brought on Jerome Adams to be part of Atea Phar­ma­ceu­ti­cals’ board of di­rec­tors. Adams was Sur­geon Gen­er­al dur­ing Pres­i­dent Trump’s ad­min­is­tra­tion and a mem­ber of the Covid-19 Task Force.

Crit­i­cal Path In­sti­tute has ap­point­ed Robert Califf to its board of di­rec­tors. Califf is the head of clin­i­cal pol­i­cy and strat­e­gy for Al­pha­bet’s Ver­i­ly Life Sci­ences and Google Health di­vi­sions. Califf for­mer­ly serves as FDA com­mis­sion­er un­der Pres­i­dent Oba­ma’s ad­min­is­tra­tion from 2016-2017.

Emi­ly Pe­ter­son Al­va

Alk­er­mes has a new board mem­ber in Emi­ly Pe­ter­son Al­va, gain­ing El­liott Ad­vi­sors’ seal of ap­proval af­ter CEO Richard Pops un­veiled a val­ue en­hance­ment plan to re­ju­ve­nate the com­pa­ny. Al­va de­vot­ed more than 15 years to Lazard as an in­vest­ment banker, is on the board at Am­neal Phar­ma­ceu­ti­cals, and is a found­ing mem­ber/cor­po­rate board part­ner with the Nas­daq Cen­ter for Board Ex­cel­lence.

→ Three’s a crowd as Ar­a­vive makes a trio of ap­point­ments to its board of di­rec­tors. John Hohnek­er, Sig­urd Kirk and Pe­ter Ho are the new­ly-mint­ed mem­bers of the team. Hohnek­er, the ex-CEO of Anokion (now led by Deb­o­rah Ger­aghty), cur­rent­ly serves on the boards of Evelo Bio­sciences and Tr­ishu­la Ther­a­peu­tics. Kirk comes from Al­ler­gan, where he served as EVP, cor­po­rate busi­ness de­vel­op­ment. Mean­while, Ho has served in roles at GSK, Epizyme, BeiGene and Boston Phar­ma­ceu­ti­cals.

El­liott Levy

Flag­ship epi­ge­net­ic pro­gram­ming start­up Omega Ther­a­peu­tics has waved in El­liott Levy as a mem­ber of the board of di­rec­tors. Levy, who just de­part­ed Am­gen and was SVP of glob­al de­vel­op­ment, is the one-time VP and head of spe­cial­ty de­vel­op­ment for Bris­tol My­ers.

Shore­line Bio­sciences has wel­comed Kim­ber­ly Man­hard to its board of di­rec­tors. Man­hard cur­rent­ly serves as EVP, drug de­vel­op­ment and di­rec­tor of Heron Ther­a­peu­tics. Pri­or to that, Man­hard had stints at Ardea Bio­sciences, Ex­elix­is, Agouron Phar­ma­ceu­ti­cals, BMS and Eli Lil­ly.

→ New York-based El­e­va­tion On­col­o­gy has giv­en a seat to long­time Ar­ray Bio­Phar­ma CFO Michael Car­ruthers on the board of di­rec­tors. Car­ruthers be­came a CFO again at Edge­wise Ther­a­peu­tics back in Oc­to­ber.

Katy Rez­vani

→ CRISPR genome edit­ing play­er Cari­bou Bio­sciences has pulled in Katy Rez­vani and Christo­pher Stur­geon to its sci­en­tif­ic ad­vi­so­ry board. Rez­vani is a pro­fes­sor of stem cell trans­plan­ta­tion and cell ther­a­py at the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter while Stur­geon is an as­so­ciate pro­fes­sor at the Ic­ahn School of Med­i­cine at Mount Sinai.

Shut­tle Phar­ma­ceu­ti­cals has added Chris Senanayake to its board of di­rec­tors. Senanayake brings with him his ex­pe­ri­ence from TCG Life­sciences, Mer­ck, Boehringer In­gel­heim and As­ta GreenChem, among oth­ers.

→ A char­i­ta­ble or­ga­ni­za­tion that looks to pro­vide life­time sup­plies of an­ti­sense oligonu­cleotide ther­a­pies to pa­tients for free, n-Lorem Foun­da­tion has en­list­ed Frank Sasi­nows­ki to its board of di­rec­tors. Sasi­nows­ki comes aboard with ex­pe­ri­ence from his stint as a reg­u­la­to­ry coun­sel for the FDA. Sasi­nows­ki is cur­rent­ly a di­rec­tor of Hy­man, Phelps & Mc­Na­ma­ra and an ad­junct pro­fes­sor of neu­rol­o­gy at the Uni­ver­si­ty of Rochester School of Med­i­cine.

Un­lock­ing ESG strate­gies for growth with Gilead Sci­ences

RBC Capital Markets explores what is material in ESG for biopharma companies with the ESG leads at Gilead Sciences. Gilead has long focused on sustainability but recognized a more robust framework was needed. Based on a materiality assessment, Gilead’s ESG strategy today focuses first on drug access and pricing, while also addressing D&I and climate change. Find out why Gilead’s board is “acutely aware” of the contribution that ESG makes to firm’s overall success.

On the hunt for the next Mod­er­na, in­vestors have pumped 'plat­form plays' with cash. Can any­thing slow the run­away train?

It didn’t take an expert to see that mRNA platforms could be huge.

Julie Sunderland partnered with both Moderna and BioNTech about a decade ago while she was running program-related investments for the Bill & Melinda Gates Foundation — and even then the potential for their platforms was obvious despite some well-founded concerns about whether the next-gen tech would ever cross the finish line.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sen. Ron Wyden (D-OR) with reporters in the Senate Subway (Graeme Sloan/Sipa via AP Images)

Top Wyden pri­or­i­ty for drug price re­forms: Medicare ne­go­ti­a­tions

As the Biden administration tries to wrangle the details of its infrastructure bill, Senate Finance Committee Chair Ron Wyden (D-OR) took a concrete step forward on drug pricing reforms on Tuesday and unveiled five principles for such reforms, including providing Medicare with the ability to negotiate prices.

“Allowing the Secretary of HHS to negotiate the price Medicare will pay creates a much needed mechanism to achieve fairer prices when the market has failed to do so,” Wyden wrote.

Roche's Alzheimer's drug spurred bio­mark­er changes but no cog­ni­tive im­pact — pa­per; vTv out-li­cens­es for­mer lead pro­gram

More than a year ago, Roche and Eli Lilly were forced to contend with a Phase II/III failure of their respective Alzheimer’s drugs. But while Eli Lilly essentially threw in the towels, Roche wasn’t ready to give up yet.

The Swiss drugmaker now has some biomarker data to spotlight as investigators continue monitoring patients in an open-label extension study.

Dubbed DIAN-TU, the study had been designed to see whether Roche’s gantenerumab and Lilly’s solanezumab could spur a cognitive benefit for a group of patients who had a rare, inherited form of Alzheimer’s that’d tied to early-onset. In short, they didn’t: Both failed the primary endpoint.

Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

In the years since I/O wonder drug Keytruda’s initial approval, Merck has struck an aggressive clinical trial program, which is now firmly focused on earlier lines of therapy. The drugmaker has scored some success there so far, and now it’s earned one of its biggest wins yet.

Keytruda plus chemotherapy with or without background Avastin significantly extended patients’ lives over those dosed with a placebo control in first-line patients with persistent, recurrent or metastatic cervical cancer, according to top-line data from the Phase III KEYNOTE-826 study revealed Tuesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.

End­points News is now 5 years old. Here's how you can sup­port us for the next phase of growth

Endpoints News turned five years old over the weekend. I wanted to mark the happy occasion by extending our deepest gratitude to Endpoints’ premium subscribers while outlining several other ways to support us as we go broader and get bigger this year and beyond.

Same as any business, we’ve got to create value and get paid for delivering it. So if you depend on Endpoints to stay abreast on biopharma developments, we depend on you too.

Emma Walmsley, GlaxoSmithKline CEO (Credit: Fang Zhe/Xinhua/Alamy Live News)

Ac­tivist in­vestor El­liott in talks with oth­er Glax­o­SmithK­line in­vestors about re­plac­ing Em­ma Walm­s­ley, spin­ning off vac­cine busi­ness — re­port

As Emma Walmsley reveals details this Wednesday about the upcoming split of GlaxoSmithKline’s pharma and consumer units, some tough questions may be coming her way.

Elliott Management, the activist investor that’s previously threatened an attack on GSK (but eventually backed off), is floating more radical changes like replacing the CEO, further breaking up the company and spinning out the vaccine unit, or reviewing the focus on cancer drugs, the Financial Times reported.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: White House re­veals vac­cine do­na­tion plan; EU opts in for an­oth­er 150 mil­lion dos­es from Mod­er­na

President Joe Biden’s administration on Monday revealed the distribution list for 55 million of the 80 million doses of Covid-19 vaccines America plans to donate to lower-income nations:

Roughly 14 million doses will head to Latin America and the Caribbean, for a list of countries that includes Brazil, Argentina, Dominican Republic, Panama and Costa Rica.
Another 16 million doses are headed to Asia to help the following countries: India, Nepal, Bangladesh, Pakistan, Sri Lanka, Afghanistan, Maldives, Bhutan, Philippines, Vietnam, Indonesia, Thailand, Malaysia, Laos, Papua New Guinea, Taiwan, Cambodia, and the Pacific Islands.

Neu­rona Ther­a­peu­tics is dash­ing to the clin­ic with its cell ther­a­py for epilep­sy — but first, an­oth­er ven­ture round

Six years ago, a band of neuroscientists from the University of California, San Francisco combined decades of research and jumped into the hunt for an off-the-shelf cell therapy. Now, that team is sprinting toward the clinic with a treatment for epilepsy — but first, it’s making a pit stop at the venture well.

Neurona Therapeutics unveiled a $41.5 million round on Tuesday morning, bringing the San Francisco-based biotech’s total raise to $135 million. The cash will be used to advance the company’s pipeline, including an upcoming Phase I/IIa for its lead candidate, NRTX-1001, in chronic focal epilepsy.